BASIC DATA SUPPORTING THE USE OF THE L-LYSINE SALT OF BENDAZAC IN CATARACT

  • 1 January 1983
    • journal article
    • research article
    • Vol. 5  (2) , 217-225
Abstract
Bendazac, as such or in the form of its L-lysine salt, has a protective effect against lens protein denaturation both in vitro and in vivo. In vitro this effect has veen documented on the lens proteins of rats, rabbits and pigs by using nephelometry, electrophoresis and EM. In vivo the protective effect has been observed after treatments ranging in duration from 3-14 days depending on the dosage used; the minimal effective dose produced a serum level of 35 .mu.g/ml of bendazac. The penetration of the drug into the lens has been shown by both radioassay and HPLC [high performance liquid chromatography]; the lens concentration of bendazac increases with the duration of treatment. The mechanism of the protective action of bendazac against lens protein denaturation is discussed together with the implications of such protective action in the treatment of cataract.

This publication has 1 reference indexed in Scilit: